15th December, 2022Thelper was pre-selected as one of the top four biotech companies to compete in the finals for the 1M NOK DNB Healthcare Prize. While we didn't win the Prize, our CEO and founder, Katja Vetvik, put up an inspiring pitch to explain how Thelper's novel anti-viral therapies can potentially transform the treatment landscape for triple negative breast cancer, and other solid tumor types with high unmet needs.
As part of the process, Katja was interviewed in a podcast hosted by Dagens Medisin, Norway's premier medical newsletter for healthcare professionals. The podcast is accessible at the following link (in Norwegian only): https://www.dagensmedisin.no/artikler/2022/12/14/tre-helsegrundere-konkurrerer-om-hederstittel/